<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00392678</url>
  </required_header>
  <id_info>
    <org_study_id>CHS 06-20, NIH U01 DK74556</org_study_id>
    <secondary_id>U01DK074556</secondary_id>
    <nct_id>NCT00392678</nct_id>
  </id_info>
  <brief_title>Targeting INflammation Using SALsalate in Type 2 Diabetes (TINSAL-T2D)</brief_title>
  <acronym>TINSAL-T2D</acronym>
  <official_title>Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Growing evidence over recent years supports a potential role for low grade chronic
      inflammation in the pathogenesis of insulin resistance and type 2 diabetes. In this study we
      will determine whether salsalate, a member of the commonly used Non-Steroidal
      Anti-Inflammatory Drug (NSAID) class, is effective in lowering sugars in patients with type 2
      diabetes. The study will determine whether salicylates represent a new pharmacological option
      for diabetes management. The study is conducted in two stages. The first stage is a dose
      ranging study, administering salsalate compared to placebo over three months. The primary
      objective of Stage 2 of the study is to evaluate the effects of salsalate on blood sugar
      control in diabetes; the tolerability of salsalate use in patients with type 2 diabetes
      (T2D); and the effects of salsalate on measures of inflammation, the metabolic syndrome, and
      cardiac risk.

      The second stage is a second trial and posted under alternate registration.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the first stage of the TINSAL-T2D trial is to select a dose of
      salsalate that is both well-tolerated and demonstrates a trend toward improvement in glycemic
      control. The trial is a multicenter, single mask lead-in, double masked placebo controlled
      dose ranging study, comparing salsalte to placebo over 3 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 14 (Stage 1) in the Intent-to-treat (ITT) Population With Last Observation Carried Forward.</measure>
    <time_frame>14 week</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Either 14 or 26 Weeks, or Last HbA1c Measurement Prior to Rescue Therapy</measure>
    <time_frame>14 week</time_frame>
    <description>see primary outcome</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline and Trends in Fasting Glucose Over Time</measure>
    <time_frame>14 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates for Reduction in Fasting Glucose of ≥20 mg/dl, a Reduction in HbA1c of ≥0.5%, and a Reduction in HbA1c of ≥0.8%</measure>
    <time_frame>14-26 week</time_frame>
    <description>This was an aim proposed for the longer duration study and is reported under TINSAL-T2D stage 2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Lipids (Low-density Lipoprotein Cholesterol [LDL-C], Non-high-density Lipoprotein Cholesterol [Non-HDL-C], Triglycerides [TG], Total Cholesterol [TC], High-density Lipoprotein Cholesterol [HDL C], TC/HDL-C Ratio, and LDL-C/HDL-C Ratio)</measure>
    <time_frame>14 week</time_frame>
    <description>LDL-C/HDL-C ratio not calculated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index</measure>
    <time_frame>Baseline, week 14</time_frame>
    <description>HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates for Exceeding Hyperglycemic Targets Between Active and Placebo Treated Groups</measure>
    <time_frame>14 week</time_frame>
    <description>Please see adverse events module for hyperglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Rescue Therapy</measure>
    <time_frame>14 weeks</time_frame>
    <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for Discontinuation of Study Medication</measure>
    <time_frame>14 week</time_frame>
    <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy</measure>
    <time_frame>14-26 week</time_frame>
    <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response Rates for a Reduction in HbA1c for Obese vs Non-obese Participants</measure>
    <time_frame>14-26 week</time_frame>
    <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability of Salsalate Compared to Placebo as Assessed by Adverse Events.</measure>
    <time_frame>14 weeks</time_frame>
    <description>See adverse event module for details.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index</measure>
    <time_frame>Baseline, week 14</time_frame>
    <description>HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">277</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salsalate 3.0 g daily, divided</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salsalate 3.0 grams daily, divided</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salsalate 3.5 g daily, divided</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salsalate 3.5 g daily, divided</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Salsalate 4.0 g daily, divided</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Salsalate 4.0 g daily, divided</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided</description>
    <arm_group_label>Salsalate 3.0 g daily, divided</arm_group_label>
    <arm_group_label>Salsalate 3.5 g daily, divided</arm_group_label>
    <arm_group_label>Salsalate 4.0 g daily, divided</arm_group_label>
    <other_name>Disalsid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Type 2 diabetes on diet and exercise therapy or monotherapy with metformin, insulin
             secretagogue, or alpha-glucosidase inhibitors, or a low-dose combination of these at ≤
             50% maximal dose (see Appendix). Dosing is stable for 8 weeks prior to randomization.

          2. FPG ≤ 225 mg/dL and HbA1c&gt;7% and ≤9.5% at screening

          3. Age ≥18 and &lt;75

          4. Women of childbearing potential agree to use an appropriate contraceptive method
             (hormonal, IUD, or diaphragm)

        Exclusion Criteria:

          1. Type 1 diabetes and/or history of ketoacidosis determined by medical history

          2. History of severe diabetic neuropathy including autonomic neuropathy, gastroparesis or
             lower limb ulceration or amputation

          3. History of long-term therapy with insulin (&gt;30 days) within the last year

          4. Therapy with rosiglitazone (Avandia) or pioglitazone (Actos), or extendin-4 (Byetta),
             alone or in combination in the previous 6 months

          5. Pregnancy or lactation

          6. Patients requiring corticosteroids within 3 months or recurrent continuous oral
             corticosteroid treatment (more than 2 weeks)

          7. Use of weight loss drugs [e.g., Xenical (orlistat), Meridia (sibutramine), Acutrim
             (phenylpropanol-amine), or similar over-the-counter medications] within 3 months of
             screening or intentional weight loss of ≥ 10 lbs in the previous 6 months

          8. Surgery within 30 days prior to screening

          9. Serum creatinine &gt;1.4 for women and &gt;1.5 for men or eGFR &lt;60 [possible chronic kidney
             disease stage 3 or greater calculated using the Modification of Diet in Renal Disease
             (MDRD) equation.

         10. History of chronic liver disease including hepatitis B or C

         11. History of peptic ulcer or endoscopy demonstrated gastritis

         12. History of acquired immune deficiency syndrome or human immunodeficiency virus (HIV)

         13. History of malignancy, except participants who have been disease-free for greater than
             10 years, or whose only malignancy has been basal or squamous cell skin carcinoma

         14. New York Heart Association Class III or IV cardiac status or hospitalization for
             congestive heart failure

         15. History of unstable angina, myocardial infarction, cerebrovascular accident, transient
             ischemic attack or any revascularization within 6 months

         16. Uncontrolled hypertension (defined as systolic blood pressure &gt;150 mmHg or diastolic
             blood pressure &gt;95 mmHg on three or more assessments on more than one day)

         17. History of drug or alcohol abuse, or current weekly alcohol consumption &gt;10 units/week
             (1 unit = 1 beer, 1 glass of wine, 1 mixed cocktail containing 1 ounce of alcohol)

         18. Hemoglobin &lt;12 g/dL (males), &lt;10 g/dL (females) at screening

         19. Platelets &lt;100,000 cu mm at screening.

         20. AST (SGOT) &gt;2.50 x ULN or ALT (SGPT) &gt;2.50 x ULN at screening

         21. Total Bilirubin &gt;1.50 x ULN at screening

         22. Triglycerides (TG) &gt;500 mg/dL at screening

         23. Poor mental function or any other reason to expect patient difficulty in complying
             with the requirements of the study

         24. Previous allergy to aspirin

         25. Chronic or continuous use (daily for more than 7 days) of nonsteroidal
             anti-inflammatory drugs within the preceding 2 months

         26. Use of warfarin (Coumadin), clopidogrel (Plavix) or other anticoagulants

         27. Use of probenecid (Benemid, Probalan), sulfinpyrazone (Anturane) or other uricosuric
             agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven E. Sheolson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Allison B. Goldfine, MD</last_name>
    <role>Study Director</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vivian Fonseca, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tulane University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kathleen Jablonski, PhD</last_name>
    <role>Study Director</role>
    <affiliation>George Washington University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myrlene Staten, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chapel Medical Group</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MedStar Research Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20003-4393</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrine Clinical Research</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32746</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30084</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tulane University</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joslin Diabetes Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska Medical Center</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaleida Health Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore Diabetes and Endocrine Associates</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.tinsal-t2d.org</url>
    <description>TINSAL-T2D website</description>
  </link>
  <reference>
    <citation>Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. Review. Erratum in: J Clin Invest. 2006 Aug;116(8):2308.</citation>
    <PMID>16823477</PMID>
  </reference>
  <reference>
    <citation>Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94. Epub 2007 Oct 24.</citation>
    <PMID>17959861</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.</citation>
    <PMID>19337387</PMID>
  </reference>
  <reference>
    <citation>Goldfine AB, Fonseca V, Jablonski KA, Chen YD, Tipton L, Staten MA, Shoelson SE; Targeting Inflammation Using Salsalate in Type 2 Diabetes Study Team. Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2013 Jul 2;159(1):1-12. doi: 10.7326/0003-4819-159-1-201307020-00003.</citation>
    <PMID>23817699</PMID>
  </reference>
  <results_reference>
    <citation>Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE; TINSAL-T2D (Targeting Inflammation Using Salsalate in Type 2 Diabetes) Study Team. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med. 2010 Mar 16;152(6):346-57. doi: 10.7326/0003-4819-152-6-201003160-00004.</citation>
    <PMID>20231565</PMID>
  </results_reference>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 25, 2006</study_first_submitted>
  <study_first_submitted_qc>October 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 26, 2006</study_first_posted>
  <results_first_submitted>February 20, 2013</results_first_submitted>
  <results_first_submitted_qc>July 25, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 26, 2013</results_first_posted>
  <last_update_submitted>November 8, 2017</last_update_submitted>
  <last_update_submitted_qc>November 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Type 2 Diabetes</keyword>
  <keyword>Inflammation</keyword>
  <keyword>Obesity</keyword>
  <keyword>Metabolic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
    <mesh_term>Sodium Salicylate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>3 private practices and 14 universities. First patient recruited February 2007; last patient end of study visit, May 2008</recruitment_details>
      <pre_assignment_details>Screening, followed by 4-week single mask placebo lead-in. 277 participants signed screening consent. Some participants were ineligible, some withdrew consent, and some had treatment side effects during placebo lead-in.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Salsalate 3.0 g/d</title>
        </group>
        <group group_id="P2">
          <title>Salsalate 3.5 g/d</title>
        </group>
        <group group_id="P3">
          <title>Salsalate 4.0 g/d</title>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="27"/>
                <participants group_id="P4" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Salsalate 3.0 g/d</title>
        </group>
        <group group_id="B2">
          <title>Salsalate 3.5 g/d</title>
        </group>
        <group group_id="B3">
          <title>Salsalate 4.0 g/d</title>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="27"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="108"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55.4" spread="9.4"/>
                    <measurement group_id="B2" value="56.7" spread="9.8"/>
                    <measurement group_id="B3" value="55.0" spread="10.2"/>
                    <measurement group_id="B4" value="55.9" spread="8.2"/>
                    <measurement group_id="B5" value="56" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="45"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="16"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 14 (Stage 1) in the Intent-to-treat (ITT) Population With Last Observation Carried Forward.</title>
        <time_frame>14 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salsalate 3.0 g/d</title>
            <description>Salsalate 3.0 g/d, divided</description>
          </group>
          <group group_id="O2">
            <title>Salsalate 3.5 g/d</title>
            <description>Salsalate 3.5 g/d, divided</description>
          </group>
          <group group_id="O3">
            <title>Salsalate 4.0 g/d</title>
            <description>Salsalate 4.0 g/d, divided</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome for the TINSAL-T2D Study is Change in HbA1c Level From Baseline to Week 14 (Stage 1) in the Intent-to-treat (ITT) Population With Last Observation Carried Forward.</title>
          <units>% (units of HbA1c)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="26"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.36" spread="0.1338" lower_limit="-0.55" upper_limit="-0.17"/>
                    <measurement group_id="O2" value="-0.34" spread="0.1361" lower_limit="-0.54" upper_limit="-0.15"/>
                    <measurement group_id="O3" value="-0.49" spread="0.1356" lower_limit="-0.69" upper_limit="-0.30"/>
                    <measurement group_id="O4" value="-0.01" spread="0" lower_limit="-0.20" upper_limit="0.19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Either 14 or 26 Weeks, or Last HbA1c Measurement Prior to Rescue Therapy</title>
        <description>see primary outcome</description>
        <time_frame>14 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Salsalate 3.0 g/d</title>
            <description>Salsalate 3.0 g/d, divided</description>
          </group>
          <group group_id="O3">
            <title>Salsalate 3.5 g/d</title>
            <description>Salsalate 3.5 g/d, divided</description>
          </group>
          <group group_id="O4">
            <title>Salsalate 4.0 g/d</title>
            <description>Salsalate 4.0 g/d, divided</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Either 14 or 26 Weeks, or Last HbA1c Measurement Prior to Rescue Therapy</title>
          <description>see primary outcome</description>
          <units>% HbA1c</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.2" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.4" lower_limit="-0.6" upper_limit="-0.2"/>
                    <measurement group_id="O3" value="-0.3" lower_limit="-0.5" upper_limit="-0.2"/>
                    <measurement group_id="O4" value="-0.5" lower_limit="-0.7" upper_limit="-0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline and Trends in Fasting Glucose Over Time</title>
        <time_frame>14 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Salsalate 3.0 g/d</title>
            <description>Salsalate 3.0 g/d, divided</description>
          </group>
          <group group_id="O3">
            <title>Salsalate 3.5 g/d</title>
            <description>Salsalate 3.5 g/d, divided</description>
          </group>
          <group group_id="O4">
            <title>Salsalate 4.0 g/d</title>
            <description>Salsalate 4.0 g/d, divided</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline and Trends in Fasting Glucose Over Time</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" lower_limit="2" upper_limit="24"/>
                    <measurement group_id="O2" value="-19" lower_limit="-30" upper_limit="-8"/>
                    <measurement group_id="O3" value="-14" lower_limit="-25" upper_limit="-3"/>
                    <measurement group_id="O4" value="-15" lower_limit="-26" upper_limit="-4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates for Reduction in Fasting Glucose of ≥20 mg/dl, a Reduction in HbA1c of ≥0.5%, and a Reduction in HbA1c of ≥0.8%</title>
        <description>This was an aim proposed for the longer duration study and is reported under TINSAL-T2D stage 2.</description>
        <time_frame>14-26 week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Lipids (Low-density Lipoprotein Cholesterol [LDL-C], Non-high-density Lipoprotein Cholesterol [Non-HDL-C], Triglycerides [TG], Total Cholesterol [TC], High-density Lipoprotein Cholesterol [HDL C], TC/HDL-C Ratio, and LDL-C/HDL-C Ratio)</title>
        <description>LDL-C/HDL-C ratio not calculated</description>
        <time_frame>14 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Salsalate 3.0 g/d</title>
            <description>Salsalate 3.0 g/d, divided</description>
          </group>
          <group group_id="O3">
            <title>Salsalate 3.5 g/d</title>
            <description>Salsalate 3.5 g/d, divided</description>
          </group>
          <group group_id="O4">
            <title>Salsalate 4.0 g/d</title>
            <description>Salsalate 4.0 g/d, divided</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Lipids (Low-density Lipoprotein Cholesterol [LDL-C], Non-high-density Lipoprotein Cholesterol [Non-HDL-C], Triglycerides [TG], Total Cholesterol [TC], High-density Lipoprotein Cholesterol [HDL C], TC/HDL-C Ratio, and LDL-C/HDL-C Ratio)</title>
          <description>LDL-C/HDL-C ratio not calculated</description>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-7" upper_limit="8"/>
                    <measurement group_id="O2" value="8" lower_limit="1" upper_limit="16"/>
                    <measurement group_id="O3" value="-1" lower_limit="-9" upper_limit="7"/>
                    <measurement group_id="O4" value="6" lower_limit="-1" upper_limit="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="3" lower_limit="1" upper_limit="4"/>
                    <measurement group_id="O3" value="1" lower_limit="-1" upper_limit="3"/>
                    <measurement group_id="O4" value="2" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-7" upper_limit="6"/>
                    <measurement group_id="O2" value="15" lower_limit="9" upper_limit="22"/>
                    <measurement group_id="O3" value="3" lower_limit="-3" upper_limit="10"/>
                    <measurement group_id="O4" value="8" lower_limit="2" upper_limit="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="-6" upper_limit="36"/>
                    <measurement group_id="O2" value="-34" lower_limit="-55" upper_limit="-13"/>
                    <measurement group_id="O3" value="-22" lower_limit="-43" upper_limit="0"/>
                    <measurement group_id="O4" value="-16" lower_limit="-38" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total to HDL ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-0.2" upper_limit="0.3"/>
                    <measurement group_id="O2" value="0.1" lower_limit="-0.1" upper_limit="0.4"/>
                    <measurement group_id="O3" value="-0.1" lower_limit="-0.3" upper_limit="0.2"/>
                    <measurement group_id="O4" value="0.2" lower_limit="-0.1" upper_limit="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index</title>
        <description>HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below.</description>
        <time_frame>Baseline, week 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Salsalate 3.0 g/d</title>
            <description>Salsalate 3.0 g/d, divided</description>
          </group>
          <group group_id="O3">
            <title>Salsalate 3.5 g/d</title>
            <description>Salsalate 3.5 g/d, divided</description>
          </group>
          <group group_id="O4">
            <title>Salsalate 4.0 g/d</title>
            <description>Salsalate 4.0 g/d, divided</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index</title>
          <description>HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in insulin from Baseline to Week 14 in data table below.</description>
          <units>pmol/l</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" lower_limit="36">NA IQR provided as Q3-Q1</measurement>
                    <measurement group_id="O2" value="15" lower_limit="27">NA IQR provided as Q3-Q1</measurement>
                    <measurement group_id="O3" value="7.6" lower_limit="29">NA IQR provided as Q3-Q1</measurement>
                    <measurement group_id="O4" value="27" lower_limit="58">NA IQR provided as Q3-Q1</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates for Exceeding Hyperglycemic Targets Between Active and Placebo Treated Groups</title>
        <description>Please see adverse events module for hyperglycemia.</description>
        <time_frame>14 week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Rescue Therapy</title>
        <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
        <time_frame>14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Need for Discontinuation of Study Medication</title>
        <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
        <time_frame>14 week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates in Patients Initially Treated With Lifestyle Modification, Insulin Secretagogue, Metformin or Combination Therapy</title>
        <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
        <time_frame>14-26 week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response Rates for a Reduction in HbA1c for Obese vs Non-obese Participants</title>
        <description>This aim was proposed for the TINSAL-T2D stage 2 trial and is separately reported.</description>
        <time_frame>14-26 week</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety and Tolerability of Salsalate Compared to Placebo as Assessed by Adverse Events.</title>
        <description>See adverse event module for details.</description>
        <time_frame>14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salsalate 3.0 g/d</title>
            <description>Salsalate 3.0 g/d, divided</description>
          </group>
          <group group_id="O2">
            <title>Salsalate 3.5 g/d</title>
            <description>Salsalate 3.5 g/d, divided</description>
          </group>
          <group group_id="O3">
            <title>Salsalate 4.0 g/d</title>
            <description>Salsalate 4.0 g/d, divided</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Safety and Tolerability of Salsalate Compared to Placebo as Assessed by Adverse Events.</title>
          <description>See adverse event module for details.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index</title>
        <description>HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below</description>
        <time_frame>Baseline, week 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Placebo</description>
          </group>
          <group group_id="O2">
            <title>Salsalate 3.0 g/d</title>
            <description>Salsalate 3.0 g/d, divided</description>
          </group>
          <group group_id="O3">
            <title>Salsalate 3.5 g/d</title>
            <description>Salsalate 3.5 g/d, divided</description>
          </group>
          <group group_id="O4">
            <title>Salsalate 4.0 g/d</title>
            <description>Salsalate 4.0 g/d, divided</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin, C-peptide, Homeostasis Model [HOMA] Index</title>
          <description>HOMA-IR was not calcuated due to potential confounding effect of salicylates to inhibit insulin clearance. Change in C-peptide from Baseline to Week 14 is in the data table below</description>
          <units>C-peptide in nmol/l</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="26"/>
                <count group_id="O4" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="0" upper_limit="0.2"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.17" upper_limit="0.01"/>
                    <measurement group_id="O3" value="-0.03" lower_limit="-0.13" upper_limit="0.10"/>
                    <measurement group_id="O4" value="0.03" lower_limit="-0.07" upper_limit="0.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Salsalate 3.0 g/d</title>
        </group>
        <group group_id="E2">
          <title>Salsalate 3.5 g/d</title>
        </group>
        <group group_id="E3">
          <title>Salsalate 4.0 g/d</title>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Congestive Heart Failure with Diastolic Dysfunction</sub_title>
                <description>Hospitalization for Congestive Heart Failure with Diastolic Dysfunction.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Cholecystitis</sub_title>
                <description>Hospitalization for Acute Cholecystitis, laparoscopic cholecystectomy performed.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Disc Herniation</sub_title>
                <description>1. Hospitalization for Cervical Disc Herniation.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lumbar laminectomy</sub_title>
                <description>Hospitalization for Lumbar laminectomy.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E4" subjects_affected="25" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiorespiratory</sub_title>
                <description>Includes palpitations, chest pain or discomfort, and swelling of legs or feet</description>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="3" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <counts group_id="E1" events="63" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E2" events="46" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal</sub_title>
                <description>incudes heartburn, nausea, vomiting, diarrhea</description>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>General</sub_title>
                <description>Includes fainting, dizziness, weakness or fatigue.</description>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal</sub_title>
                <description>Includes stiffness, muscle or joint pain, arthritis, backache.</description>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E4" events="9" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neurologic</sub_title>
                <description>Includes blurry vision, dots or flashes in vision, tinnitus, and numbness or tingling.</description>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="27"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Allison B. Goldfine, MD co-investigator</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617-309-2643</phone>
      <email>allison.goldfine@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

